Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dubious Ukrainian drugs deals involve GSK and Sanofi-Pasteur vaccines

This article was originally published in Scrip

Executive Summary

An investigation conducted at the request of Ukraine's government has put price differentials for vaccines produced by GlaxoSmithKline, Sanofi-Pasteur and Denmark's Statens Serum Institute (SSI) at the centre of an alleged illegal pharmaceuticals procurement scandal. The investigation has shown that at least four Ukrainian pharmaceutical suppliers were using similar schemes of importing drugs through foreign and domestic shell companies to overcharge the health ministry. The investigation specifically pinpointed fraud and waste of budget funds in the health ministry's purchase of pharmaceuticals worth more than Hr250 million ($30 million) in 2008-09. Although $30 million represented a small part of $2.7 billion retail drug sales in Ukraine, the story illustrates a malaise which many observers believe is probably more widespread. Furthermore, the investigation also recommends that current Ukrainian state procurement protocols will need to be upgraded in order to prevent repetition of the affair.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts